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LY 255283 [(1-(5-ethyl-2-hydroxy-4-(6-methyl-6-)lH-
tetrazol-5-yl)-heptyloxy) phenyl)ethanone], a specific
leukotriene B (LTB4) receptor antagonist, inhibited the
production of LTB4 in human peripheral blood poly-
morphonuclear leukocytes (PMNL) and in monocytes
activated by calcium ionophore A23187. In human
monocytes activated by ionophore it inhibited also the
production of thromboxane B (TXB2). The effect of LY
255283 on 5-1ipoxygenase (5-LO) and LTA hydrolase
activities which catalyse the production of LTB4 and
LTA has not been studied yet. It is thought that LY 255283
may inhibit the production of LTB and TXA2 by
antagonising the effect of ionophore-induced LTB on
5-1ipoxygenase and cyclooxygenase in human peripheral
blood PMNL and monocytes.
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Introduction
LTB4, a 5-1ipoxygenase metabolite of arachidonic
acid (AA), is an inflammatory mediator released
from immunoinflammatory ceils, especially from
neutrophils and monocytes. A variety of stimuli,
including calcium ionophores, particulate (zymo-
san) and soluble stimuli (N-formyl-methionyl-
leucyl-phenylalanine) and complement component
CSa1’2 can elicit the synthesis of LTB4 from
neutrophil and monocytes.
It has been shown that LTB4 stimulates various
neutrophil functions such as chemotaxis, adherence,
aggregation and degranulation.
3 LTB4 also has
4 some effects on the function of monocytes.
Increased levels ofLTB4 have been shown during
various immunoinflammatory conditions, s’6 Since
LTB4 is accepted as an inflammatory mediator and
the level of LTB4 is increased during various
immunoinflammatory conditions, several 5-1ipoxy-
genase inhibitors and LTB4 receptor antagonists
are developed for the purpose of obtaining an
effective antiinflammatory drug.
7
Recently, McDonald et al. have shown that
exogenously applied LTB4 activates the human
neutrophil 5-1ipoxygenase and causes the over-
production of LTB4.
8 During our ongoing studies
with LTB4 receptor antagonists, we have observed
that LY 2455283, a specific LTB4 antagonist, can
inhibit calcium ionophore A23187-induced LTB4
synthesis in human neutrophils, monocytes and
TXB2 synthesis in monocytes.
Materials and Methods
Ce// separation: Citrated blood was collected by
venipuncture from healthy volunteers who had
abstained from any drugs for at least 1 week
before the sampling. A method described by
Dewar was used for the isolation of human
PMNL and monocytes.
1 Briefly, platelet rich
plasma was discarded after the centrifugation of
whole blood. Mononuclear cells and PMNL were
separated by centrifugation on Ficoll-Paque cush-
ions. The PMNL were separated from erythrocytes
by dextran sedimentation and NH4C1 lysis. After the
isolation procedure, the purity of PMNL was
> 98% and viability determined by Trypan blue
exclusion > 95%. Monocytes were further purified
by adherence. 1.5 ml portions of the mononuclear
cell suspension (2 x 106 cells/ml) were layered
onto 30 mm plastic tissue culture dishes (Greiner)
and were incubated at 37C under an atmosphere
of 5% CO2 and 95% air for 1 h. The nonadherent
cells were removed and additional 1.5 ml portions
of mononuclear cell suspension (2 x 106 cells/ml)
were added to each plate and the same incubation
protocol was repeated. By quantitation of the
adherent cells, it was determined that 85 to 90%
of the adherent cells were monocytes.
Ce//incubation: Incubations were performed at 37C
under an atmosphere of 5% CO2 and 95% air.
PMNL (4 x 106 cells/ml) were suspended in
Dulbecco’s phosphate buffered saline containing
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Ca2+/Mg2+ (DPBS + +) (composition in g/1
NaC1 8, KC1 0.2, Na2HPO4 1.15, KH2PO4 0.2,
MgC12.6H20 0.1 and CaC12 0.1) in tissue culture
tubes (Greiner). After 10 min preincubation with
LY 255283, PMNL were stimulated with 1/M
A23187. After an incubation period of 5 min, the
cell suspension was centrifuged and the supernatant
was stored at -70C until the quantitation of LTB4
and TXB2.
The monocyte monolayers were washed and
fresh Dulbecco’s modified eagle medium (DMEM)
containing 5% foetal calf serum was added. After
10min preincubation with LY 255283 (10
-6 M),
monolayers were stimulated with 1 #M A23187.
The supernatants were decanted, centrifuged and
stored at -70C.
Enzyme immunoassay experiments: LTB4 and TXB2 were
measured by enzyme immunoassay (EIA).
11 The
assay was performed in a total volume of 150 #1
with each of the following components being added
in a 50 #1 volume: standards or biological samples,
enzymatic tracer and specific antiserum. After
overnight incubation at room temperature, the
plates were washed and 200/1 Ellman’s reagent was
dispensed into each well. After 1-2h, the
absorbance at 405 nm of each well was measured.
A standard curve from 15 pg/ml to 1 ng/ml was
used in order to evaluate the concentrations of
LTB4 and TXB2. Results are calculated in terms of
per cent of B/Bo.
Chemicals: Calcium ionophore A23187 was pur-
chased from Sigma Chemical Company (St Louis,
MO). Monoclonal anti-rabbit IgG, standards and
enzymatic tracers of LTB4 and TXB2 and antibody
to LTB4 were purchased from Cayman Chemical
Company (Ann Arbor, MI). DMEM was purchased
from Gibco BRL (Middlesex, UK). LY 255283
and antibody to TXB2 were kindly provided by
Thomas L. Jeatran (Lilly Research Laboratories,
Indianapolis), and Professor GianCarlo Folco
(Institute of Pharmacological Sciences, University
of Milan) respectively. A23187 and LY 255283 were
dissolved in absolute ethanol and dimethylsulfoxide
respectively and were diluted with DPBS + +.
Statistics: The results are expressed in ng/106 cells
and ng/dish for PMNL and monocytes respectively.
The statistical assessment of groups was made by
using a nonparametric method, Mann-Whitney-
Wilcoxon test. The minimal level of significance
was considered as p < 0.05.
Results
Calcium ionophore A23187 (10
-6 M) elicited an
increase in the synthesis of LTB4 and TXB2 in
human PMNL and monocytes. This increase was
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FIG. 1. Inhibition by LY 255283 (10
-6 M) of the A23187-induced
(10-6M) increase of LTB4 (*p < 0.0007) in human PMNL.
number of experiments.
more prominent on the synthesis of LTB4,
especially in monocytes (Figs 1 and 2).
LTB4 receptor antagonist LY 255283, at the
concentration of 10
-6 M, significantly inhibited the
ionophore-induced LTB4 synthesis in both cell
types (Figs 1 and 2). In preliminary experiments,
LY 255283 (ranging from 10
-9 to 10-6 M) caused
a dose-dependent inhibitory effect on LTB4 release
(data not shown). LY 255283 also inhibited the
synthesis of TXB2, the stable metabolite ofTXA2 in
monocytes (Fig. 2). However, LY 255283 did not
significantly inhibit the synthesis ofTXB2 in PMNL
(Fig. 1).
Discussion
It is well known that a variety of stimuli,
including the calcium ionophore A23187, can elicit
an increase in the synthesis of cyclooxygenase
(prostaglandin E2, prostacylin, TXA2) and lipoxy-
genase (mainly LTB4) metabolites of AA in human
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FIG. 2. Inhibition by LY 255283 (10
-6 M) of the A23187-induced
(10
-6 M) increase of LTB4 (*p< 0.001) and TXB2 (**p < 0.003) in
human monocytes. number of experiments.
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PMNL and monocytes. 1’2 In the present study,
calcium ionophore A23187, produced an increase in
the synthesis of LTB4 and TXB2 in these cells. The
ionophore-induced synthesis of LTB4 was more
prominent than that of TXB2, a finding which
supports previous observation of Moroney et al.
2
LTB4 is also known as one of the activators of
human PMNL and monocytes. It is therefore
expected that LTB4 may activate its own synthesis
in these cells. McDonald et al. have described that
14,15-dideuterio-LTB4 (D2-LTB4) activates 5-
lipoxygenase in PMNL and elicits an increase of
LTB4 synthesis. In this study, increased synthesis
of LTB4 by D2-LTB4 in PMNL occurred when the
cells were incubated with exogenous AA. It is well
known that synthesis of LTB4 from endogenous
AA results from the activation of two independent
calcium-dependent events. First, the release of AA
from membrane phospholipids and second, the
activation of the 5-LO.
3 In the present study,
calcium ionophore A23187 increases Ca
2+ influx as
well as intracellular Ca2+ and therefore causes the
release of AA from membrane phospholipids and
activation of 5-LO.
Another interesting facet of the present study is
that LY 255283 causes a decrease in the level of
TXB2 in monocytes. LTB4 increases PGE2 and
TXA2 synthesis in rat peritoneal macrophages
elicited by carrageenin injection.
4 The results of the
present study indicate that LY 255283 inhibited the
synthesis of TXB2 of human peripheral monocytes,
one of another mononuclear cell population. A
possible explanation of this result is that the increase
of LTB4 induced by ionophore may activate the
cyclooxygenase in human peripheral monocytes;
therefore, this may increase the synthesis of TXA2.
LY 255283 may decrease the level of TXB2 in
monocytes by inhibiting the synthesis of LTB4.
One can assume that the LTB4 receptor blocker,
LY 255283, may also suppress the synthesis ofLTB4
by inhibiting 5-LO or LTA4 hydrolase. Such an
effect of the compound has not been described
previously by other investigators yet and needs
further studies using purified 5-LO or LTA4
hydrolase.
In conclusion, besides LTB4’s activation of
immunoinflammatory cells like human peripheral
PMNL and monocytes, LTB4 can also activate its
own synthesis in these cells and activate the
synthesis of TXB2 in human monocytes. LTB4
receptor antagonists may provide an additional
useful effect by antagonising the self-stimulatory
effect of LTB4.
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